Progyny, Inc.

Equities

PGNY

US74340E1038

Managed Healthcare

Real-time Estimate Cboe BZX 12:01:34 2024-03-28 pm EDT 5-day change 1st Jan Change
38.68 USD +1.82% Intraday chart for Progyny, Inc. +5.13% +4.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Progyny, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Progyny Insider Sold Shares Worth $403,260, According to a Recent SEC Filing MT
Progyny Announces $100 Million Share Repurchase Program; Shares Rise MT
Progyny, Inc. announces an Equity Buyback for $100 million worth of its shares. CI
Progyny, Inc. authorizes a Buyback Plan. CI
Progyny Shares Slump After Q4 Results MT
KeyBanc Adjusts Price Target on Progyny to $43 From $45, Maintains Overweight Rating MT
North American Morning Briefing : Stock Futures Fall Ahead of Key Inflation Data DJ
Progyny Q4 Adjusted Earnings, Revenue Rise MT
Transcript : Progyny, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024 CI
Earnings Flash (PGNY) PROGYNY Reports Q4 EPS $0.32, vs. Street Est of $0.12 MT
Earnings Flash (PGNY) PROGYNY Reports Q4 Revenue $269.9M, vs. Street Est of $274.1M MT
(PGNY) PROGYNY Forecasts Fiscal Year 2024 EPS $1.54 - $1.59 MT
Progyny, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Progyny Insider Sold Shares Worth $769,928, According to a Recent SEC Filing MT
Progyny Chosen as Preferred Fertility Benefits Provider by Vistia Health MT
Vistia Health Selects Progyny, Inc. as Its Preferred Fertility and Family Building Benefits Provider CI
Progyny Names Chief Commercial Officer, Chief Technology Officer MT
Progyny Insider Sold Shares Worth $2,500,156, According to a Recent SEC Filing MT
Progyny, Inc. Announces Executive Appointments CI
Transcript : Progyny, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM
Progyny Insider Sold Shares Worth $605,106, According to a Recent SEC Filing MT
Progyny Insider Sold Shares Worth $914,745, According to a Recent SEC Filing MT
Progyny Insider Sold Shares Worth $5,898,285, According to a Recent SEC Filing MT
Chart Progyny, Inc.
More charts
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
37.99 USD
Average target price
46.9 USD
Spread / Average Target
+23.45%
Consensus